Spots Global Cancer Trial Database for immunoproliferative disorders
Every month we try and update this database with for immunoproliferative disorders cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | NCT05804032 | Multiple Myelom... | Isatuximab Isatuximab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT03373019 | Chidamide Lymphoma, B-Cel... Lymphoma, Large... Neoplasm by His... Neoplasms Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... Lymphoma, Non-H... Cyclophosphamid... Rituximab Gemcitabine Cisplatin Dexamethasone HDAC Inhibitor | Chidamide combi... | 18 Years - 75 Years | Fudan University | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | NCT01471782 | Acute Lymphobla... | Blinatumomab | - 17 Years | Amgen Research (Munich) GmbH | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT01466179 | Acute Lymphobla... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma | NCT00435916 | Lymphoma, Large... Lymphoma, Non-H... | SGN-40 | 18 Years - | Seagen Inc. | |
| Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | NCT00655837 | Lymphoma, Large... Lymphoma, Non-H... | SGN-40 rituximab gemcitabine | 18 Years - | Seagen Inc. | |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia | NCT02733042 | Lymphoma Leukemia, Lymph... | Durvalumab Lenalidomide Rituximab Ibrutinib Bendamustine | 18 Years - | Celgene | |
| A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | NCT04104776 | Advanced Solid ... Diffuse Large B... Lymphoma, T-Cel... Mesothelioma, M... Prostatic Neopl... Endometrial Can... Ovarian Clear C... | CPI-0209 | 18 Years - | Constellation Pharmaceuticals | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT01741792 | Diffuse Large B... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | NCT05066165 | Acute Myeloid L... | Arm 1: NTLA-500... Arm 2: NTLA-500... | 18 Years - | Intellia Therapeutics | |
| ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) | NCT02670564 | Acute Lymphobla... | Pharmacogenomic... Busulfan plasma... | - 18 Years | Swiss Pediatric Oncology Group | |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | NCT01183949 | Multiple Myelom... | AT7519M Bortezomib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | NCT00701844 | Leukemia Acute Leukemia Acute Lymphocyt... Multiple Myelom... Hematological C... Psychological D... | Writing A (Expe... Writing B (Expe... Writing C (Cont... Writing D (Cont... | 18 Years - | University of North Carolina, Chapel Hill | |
| Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors | NCT00701844 | Leukemia Acute Leukemia Acute Lymphocyt... Multiple Myelom... Hematological C... Psychological D... | Writing A (Expe... Writing B (Expe... Writing C (Cont... Writing D (Cont... | 18 Years - | University of North Carolina, Chapel Hill | |
| A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT05431179 | Lymphoma, Mantl... Lymphoma Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... Lymphoma, Non-H... Lymphoma, B-Cel... | Zilovertamab Ibrutinib Placebo | 18 Years - | Oncternal Therapeutics, Inc | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | NCT02112526 | Activated B-cel... | Acalabrutinib | 18 Years - 130 Years | Acerta Pharma BV | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) | NCT05529524 | Follicular Lymp... | 18 Years - | The Lymphoma Academic Research Organisation | ||
| Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | NCT02690545 | Lymphoma Lymphoma, Non-H... Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Neoplasms by Hi... | ATLCAR.CD30 cel... | 3 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | NCT03696784 | Lymphoma Lymphoma, B-Cel... Immune System D... Immunoprolifera... Lymphatic Disea... | iC9-CAR19 T cel... Bendamustine Fludarabine AP1903 Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | NCT00773747 | Multiple Myelom... | Vorinostat bortezomib placebo to vori... | 18 Years - | Merck Sharp & Dohme LLC | |
| Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | NCT03016377 | Acute Lymphobla... Immune System D... Immunoprolifera... | iC9-CAR19 cells Rimiducid Cyclophosphamid... Fludarabine | 3 Years - 70 Years | UNC Lineberger Comprehensive Cancer Center | |
| A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) | NCT01667133 | Chronic Myeloid... Philadelphia Ch... | ponatinib - Pha... ponatinib - Pha... | 18 Years - | Takeda | |
| Lymphoma Epidemiology of Outcomes Cohort Years 6-10 | NCT04996706 | Lymphoma, Non-H... | 18 Years - | Mayo Clinic | ||
| SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | NCT00365274 | Anaplastic Larg... | Cyclophosphamid... Doxorubicin hyd... vincristine sul... prednisone SGN-30 | 18 Years - | National Cancer Institute (NCI) | |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | NCT03744676 | Lymphoma, Non-H... Lymphoma Lymphoma, B-Cel... Lymphoma, Large... Neoplasms Neoplasms by Hi... Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... | lisocabtagene m... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | NCT04097067 | Follicular Lymp... Marginal Zone L... | Radiation Thera... | 18 Years - | University Hospital Muenster | |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | NCT04904588 | Acute Lymphobla... Acute Myelogeno... Mixed Phenotype... Acute Leukemia Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Lymphoma | Busulfan Busulfan Fludarabine Total-body irra... Cyclophosphamid... Melphalan PBSC Hematopoie... Bone Marrow Hem... Post-transplant... Mesna Tacrolimus Mycophenolate M... Patient-Reporte... | 1 Year - | Center for International Blood and Marrow Transplant Research | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | NCT01990534 | Hodgkin Lymphom... | Brentuximab Ved... | 18 Years - | Takeda | |
| Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma | NCT00435916 | Lymphoma, Large... Lymphoma, Non-H... | SGN-40 | 18 Years - | Seagen Inc. | |
| A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | NCT00529503 | Lymphoma, Large... Lymphoma, Non-H... | SGN-40 placebo rituximab etoposide carboplatin ifosfamide | 18 Years - 75 Years | Seagen Inc. | |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | NCT01183949 | Multiple Myelom... | AT7519M Bortezomib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma | NCT00525447 | Multiple Myelom... | SGN-40 lenalidomide dexamethasone | 18 Years - | Seagen Inc. | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT01741792 | Diffuse Large B... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | NCT02663297 | Hodgkin Disease Lymphoma Lymphoma, Non-H... Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Neoplasms by Hi... | ATLCAR.CD30 cel... | 3 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT02393859 | Leukemia, Acute... | Blinatumomab Dexamethasone Vincrisitne Daunorubicin Methotrexate Ifosfamide PEG-asparaginas... Erwinia-asparag... | 0 Years - 17 Years | Amgen | |
| A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | NCT00529503 | Lymphoma, Large... Lymphoma, Non-H... | SGN-40 placebo rituximab etoposide carboplatin ifosfamide | 18 Years - 75 Years | Seagen Inc. | |
| Lymphoma Epidemiology of Outcomes Cohort Years 6-10 | NCT04996706 | Lymphoma, Non-H... | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
